Share This Author
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
Using neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the Cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.
Alpha emitter radium-223 and survival in metastatic prostate cancer.
In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival and was associated with low myelosuppression rates and fewer adverse events.
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
- N. Vogelzang, J. Rusthoven, P. Paoletti
- Medicine, BiologyJournal of clinical oncology : official journal…
- 15 July 2003
Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.
Cancer-related fatigue is common among cancer patients who have received chemotherapy and results in substantial adverse physical, psychosocial, and economic consequences for both patients and caregivers.
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
- S. Halabi, E. Small, N. Vogelzang
- MedicineJournal of clinical oncology : official journal…
- 1 April 2003
This model could be used to predict individual survival probabilities and to stratify metastatic HRPC patients in randomized phase III trials.